drugset
drugset / Trial / NCT01003678

Safety and Tolerability of Oral Clofarabine in Intermediate to High Risk Myelodysplastic Patients

NCT01003678 ↗

Phase 1 Terminated 4 enrolled Roswell Park Cancer Institute Genzyme, a Sanofi Company · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase I trial for patients with intermediate or high risk myelodysplastic syndrome (MDS). The study agent, clofarabine, is produced by Genzyme Pharmaceuticals.

Timeline

Start
2009-10
Primary completion
2013-06
Completion
2013-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Clofarabine Other / unclassified 1 mg Oral
Subject Clofarabine Other / unclassified 3 mg Oral
Subject Clofarabine Other / unclassified 5 mg Oral
Subject Clofarabine Other / unclassified 10 mg Oral
Subject Clofarabine Other / unclassified 15 mg Oral

Indications

myelodysplastic syndrome